SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the American Society of Hematology's 49th Annual Meeting

DUBLIN, Calif., Dec. 3, 2007 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that multiple abstracts have been accepted for presentation at the American Society of Hematology's 49th Annual Meeting from Dec. 8-11 at the Georgia World Congress Center in Atlanta.

The poster presentations will focus on data regarding two of SuperGen's current oncology programs that target PIM and JAK2 kinases in hematological malignancies, respectively.

The oral presentation will focus on data from the induction of fetal hemoglobin in baboons using a novel hypomethylating agent, S110, to ameliorate symptoms associated with sickle cell anemia.

    SuperGen's schedule of presentations is as follows:

 

    Date         Time (EDT) and         Abstract # and Title     Poster Number
                    Location
    Sunday,    9:00 a.m. - 8:00 p.m.    #2655 - Targeting PIM         845
    Dec. 9     5:30 p.m. - 7:30 p.m.   Kinases in Hematological
                   Hall B3 & B4             Malignancies

    Monday,    10:30 a.m. - 7:00 p.m.  #3560 - Targeting the JAK2     779
    Dec. 10     5:00 p.m. - 7:00 p.m.    Kinase in Hematological
                   Hall B3 & B4               Malignancies

    Monday,      Oral Presentation      #571 - Fetal Hemoglobin       N/A
    Dec. 10    1:30 p.m. - 3:00 p.m.     Induction in Baboons
                                         (P. Anubis) Following
                 Rooms B216 - B217        Administration of a
                                            Novel Decitabine
                                           Dinucleotide (S110)
                                               Compound

    About SuperGen
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

    Contacts
    Timothy L. Enns                             Mary M. Vegh
    SuperGen, Inc.                              SuperGen, Inc.
    SVP, Corporate Communications & Business    Manager, Investor
    Development                                 Relations
    Tel: (925) 560-0100                         Tel: (925) 560-2845
    E-mail: tenns@supergen.com                  E-mail: mary.vegh@supergen.com

SOURCE  SuperGen Inc.
    -0-                             12/03/2007
    /CONTACT:  Timothy L. Enns, SVP, Corporate Communications & Business,
+1-925-560-0100, tenns@supergen.com; or Mary M. Vegh, Manager, Investor
Relations, +1-925-560-2845, mary.vegh@supergen.com, both of SuperGen Inc./
    /Web site:  http://www.supergen.com /

CO:  SuperGen Inc.
ST:  Georgia, California
IN:  MTC HEA
SU:  TDS SVY

GK-RF
-- NYM044 --
5602 12/03/2007 08:00 EST http://www.prnewswire.com

 

Posted: December 2007

View comments

Hide
(web2)